A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

被引：2
|
作者：
Cortiula, F. [1 ,2 ]
Naidoo, J. [3 ,4 ,5 ]
机构：
[1] Univ Hosp Udine, Dept Oncol, Udine, Italy
[2] Maastricht Univ, Sch Oncol & Reprod GROW, Maastricht, Netherlands
[3] Beaumont Hosp, Dublin, Ireland
[4] RCSI Univ Hlth Sci, Dublin, Ireland
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA
来源：
LUNG CANCER | 2023年 / 181卷
关键词：
CELL LUNG-CANCER; OPEN-LABEL; MULTICENTER; BENEFIT;
D O I：
10.1016/j.lungcan.2023.107256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [41] Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
    Zang, Hongjing
    Qian, Guoqing
    Arbiser, Jack
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Fan, Songqing
    Sun, Shi-Yong
    MOLECULAR ONCOLOGY, 2020, 14 (04) : 882 - 895
  • [42] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
    Mohorcic, K.
    Janzic, A.
    Janzic, U.
    Rot, M.
    Kern, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
  • [43] Neoadjuvant Osimertinib with/without Chemotherapy versus Chemotherapy in Patients with EGFR-mutated resectable NSCLC: NeoADAURA
    Griesinger, F.
    Tsuboi, M.
    Weder, W.
    Escriu, C.
    Blakely, C.
    He, J.
    Dacic, S.
    Yatabe, Y.
    Zeng, L.
    Walding, A.
    Chaft, J.
    PNEUMOLOGIE, 2021, 75 : S6 - S7
  • [44] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [45] Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo V.
    Nilsson, Monique B.
    Robichaux, Jacqulyne
    Boyle, Theresa
    Hicks, J. Kevin
    Lovinger, Katherine L.
    Roarty, Emily
    Rinsurongkawong, Waree
    Tang, Ming
    Sun, Huiying
    Elamin, Yasir
    Lacerda, Lara C.
    Lewis, Jeff
    Roth, Jack A.
    Swisher, Stephen G.
    Lee, J. Jack
    William, William N., Jr.
    Glisson, Bonnie S.
    Zhang, Jianjun
    Papadimitrakopoulou, Vassiliki A.
    Gray, Jhanelle E.
    Heymach, John V.
    CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6195 - 6203
  • [46] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
    Jassem, Jacek
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 808 - 810
  • [47] EGFR-mutant NSCLC: emerging novel drugs
    Ye, Lingyun
    Chen, Xiaoxia
    Zhou, Fei
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (01) : 87 - 94
  • [48] Amivantamab OK'd for EGFR-Mutant NSCLC
    Dolgin, Elie
    CANCER DISCOVERY, 2021, 11 (07) : 1604 - 1604
  • [49] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
  • [50] Using Population Dynamics Mathematical Modeling to Optimize an Intermittent Dosing Regimen for Osimertinib in EGFR-Mutant NSCLC
    Le, X.
    Chakrabarti, S.
    Michor, F.
    Costa, D.
    Meyerson, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1849 - S1849
12345